M.M. Dillon & Co acted as a financial advisor to Cardax Inc (OTC CDXI ) in its registered public exchange offer for 27.5 million warrants into newly issued warrants and a subsequent exercise into 9.8 million shares of Cardax common stock. This is the second assignment that M.M. Dillon has completed for Cardax.
Cardax, Inc., a life sciences company, develops and commercializes consumer health and pharmaceutical products for anti-inflammatory benefits primarily in Hawaii. It offers ZanthoSyn, an astaxanthin dietary supplement for health and longevity. The company sells its products primarily through e-commerce and wholesale channels. The company has a joint development and supply agreement with BASF SE, as well as a collaboration agreement with Capsugel US, LLC for the development of astaxanthin products for the consumer health market. Cardax, Inc. was incorporated in 2012 and is based in Honolulu, Hawaii
About M.M. Dillon & Co.
M.M. Dillon & Co. (formerly CRT Investment Banking LLC) is an employee owned partnership where industry and product specialists collaborate closely to provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services. M.M. Dillon’s team of experienced professionals provides execution capabilities for companies across a range of industry sectors. The firm’s senior banking professionals have a minimum of 20 years of experience with major Wall Street firms.